antibody-radionuclide-conjugate

April 18, 2018

Humalutin Inhibits Tumor Growth in Non-Hodgkin’s Lymphoma, Preclinical Study Shows

News

Humalutin (177Lu-NNV003), a novel tumor-targeting antibody labeled with radiation, demonstrated promising results in animal models of non-Hodgkin’s lymphoma (NHL), Nordic Nanovector announced. Humalutin is an investigational, humanized version of Betalutin — Nordic’s lead therapy candidate ... Read more

October 25, 2017

Pre-treatment with CD37 Antibody Enhances Amount of Betalutin to NHL Tumors, Study Finds

News

Preliminary trial results show that pre-treatment with the antibody lilotomab may increase the amount of Nordic Nanovector‘s investigational therapy Betalutin that reaches tumor lesions in patients with non-Hodgkin’s lymphoma (NHL). Representatives from ... Read more

May 4, 2017

Nordic Nanovector to Update Data on Betalutin in Non-Hodgkin’s Lymphoma Trial at June Meeting

News

Nordic Nanovector will present new data from the Phase 1/2 trial (NCT01796171) of its investigational treatment Betalutin for relapsed or treatment-resistant non-Hodgkin’s lymphoma at the International Conference on Malignant Lymphoma, ... Read more

March 27, 2017March 28, 2017

Phase 1 Study of Betalutin for Diffuse Large B-cell Lymphoma Gets Underway

News

A Phase 1 trial evaluating Betalutin, an anti-CD37 antibody attached to a radioactive compound, in patients with relapsed diffuse large B-cell lymphoma (DLBCL) has dosed its first participant. The trial ... Read more